Joel McComb

Joel McComb discloses dealings in 2 companies, chiefly Illumina, Inc. and Avid Bioservices, Inc. Over a trading history stretching from 28 January 2009 to 20 September 2018, the count stands at 7 filings.

Market trades split into 1 purchase (€90k) and 3 sales (€446k). Netting one side against the other leaves €356k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 2 share grants and 1 option exercise. So far in 2018, the count stands at 1 purchase and 2 sales.

The newest entry dates from 21 September 2018: an open-market sale of €143k, in Avid Bioservices, Inc. The most recent open-market purchase was published on 20 February 2018, 3,184 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.